ERBB2 and breast carcinoma: Women ages 18–70 with anatomic stage I–III unilateral HER2+ breast carcinoma were eligible for Translational Research in Oncology (TRIO)-B07, registered as NCT00769470 (www.clinicaltrials.gov).